Filip Van den Bosch

Clinical Observations programme in SpA: disease parameters, treatment options and practical management issues (2009)

Elewaut, Dirk, VAN DEN BOSCH, FILIP, Verbruggen, August, De Keyser, Filip, Vander Cruyssen, Bert, Mielants, Herman

Spondyloarthritides (SpAs) are a cluster of chronic inflammatory rheumatic diseases that typically involve inflammation of axial and peripheral joint or tendon and ligament insertions, distinct...

Reversible changes in serum immunoglobulin galactosylation during the immune response and treatment of inflammatory autoimmune arthritis (2009)

Van Beneden, Katrien, Coppieters, Ken, Laroy, W, De Keyser, Filip, Hoffman, Ilse, VAN DEN BOSCH, FILIP, ...

Objectives: Improved DNA sequencer-aided fluorophore-assisted carbohydrate electrophoresis (DSA-FACE) technology was used to monitor the changes in the galactosylation status of serum immunoglobulins...

Spinal radiographic changes in ankylosing spondylitis: association with clinical characteristics and functional outcome (2009)

Boonen, Annelies, Vander Cruyssen, Bert, De Vlam, Kurt, Steinfeld, Serge, Ribbens, Clio, Lenaerts, Jan, ...

Objective. To determine which patients with ankylosing spondylitis (AS) have radiographic spinal damage and to investigate the relation between radio,graphic spinal changes and limitations in...

Spontaneous amelioration in early RA: Role of antibody profiles in predicting decrease of disease activity (2008)

Vander Cruyssen, Bert, MILTENBURG, AMM, VAN DEN BOSCH, FILIP, HOUBIERS, J, Wittoek, Ruth, BOOTS, AMH, ...

Tapering infliximab dosages after temporary dose increase does not affect treatment survival in an established RA population (2008)

Vander Cruyssen, Bert, WESTHOVENS, R, DUREZ, P, VAN DEN BOSCH, FILIP, Mielants, Herman, DE CLERCK, L, ...

Agreement between evidence and Belgian rheumatologists' experience on HLA B27 determination in patients with specific imaging features in ankylosing spondylitis (2008)

Wittoek, Ruth, De Vlam, Kurt, FRANCOIS, R, GOTLIEB, L, LENAERTS, J, VAN DEN BOSCH, FILIP, ...

Agreement between evidence and Belgian rheumatologists' experience on the use of DMARDs for arthritis and/or enthesitis in ankylosing spondylitis (2008)

Wittoek, Ruth, De Vlam, Kurt, FRANCOIS, R, GOTLIEB, L, LENAERTS, J, VAN DEN BOSCH, FILIP, ...

The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice (2007)

VANDER CRUYSSEN, BERT, RIBBENS, C, BOONEN, A, Mielants, Herman, De Vlam, Kurt, LENAERTS, J, ...

Decrease of disease activity under ineffective therapy in DMARD-naive patients with early rheumatoid arthritis: Role of antibody profiles and carriage of the HLA shared epitope in predicting decrease of disease activity (2007)

VANDER CRUYSSEN, BERT, MILTENBURG, AMM, Van Den Bosch, Filip, HOUBIERS, JGA, Wittoek, Ruth, BOOTS, AMH, ...

A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip (2007)

LUYTEN, FP, GEUSENS, P, MALAISE, M, DE CLERCK, L, WESTHOVENS, R, RAEMAN, F, ...

Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo (2007)

VANDER CRUYSSEN, BERT, De Keyser, Filip, KRUITHOF, ELLI, Mielants, Herman, Van Den Bosch, Filip

Prediction of dose escalation for rheumatoid arthritis patients under infliximab treatment (2006)

Cruyssen, Bert Vander, Meeus, Jeroen, Wyns, Bart, Durez, Patrick, ...

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that leads to irreversible joint destruction. To prevent this, new biological therapies, such as infliximab, have been successfully...

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity (2006)

Van Looy, Stijn, Wyns, Bart, Durez, Patrick, Van Den Bosch, Filip, ...

Although there is strong evidence supporting the short-term efficacy and safety of anti-tumour necrosis factor-alpha agents, few studies have examined the long-term effects. We evaluated 511 patients...

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity (2006)

Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, Westhovens, Rene, Durez, Patrick, Van Den Bosch, Filip, ...

Abstract Although there is strong evidence supporting the short-term efficacy and safety of anti-tumour necrosis factor-α agents, few studies have examined the long-term effects. We evaluated 511...

Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis (2006)

Baeten, Dominique, HOUBIERS, J, KRUITHOF, ELLI, Vandooren, Bernard, Van Den Bosch, Filip, BOOTS, AM, ...

Anti-TNF-alpha therapy in ankylosing spondylitis (2006)

De Keyser, Filip, Van Den Bosch, Filip, Mielants, Herman

Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple dmard treatment: Long-term clinical effect and prediction of attrition (2006)

Vander Cruyssen, Bert, WESTHOVENS, R, DUREZ, P, Van Den Bosch, Filip, Mielants, Herman, DE CLERCK, L, ...

Which patients with ankylosing spondylitis start anti-TNF-alpha therapy in daily clinical practice? (2006)

Vander Cruyssen, Bert, Mielants, Herman, BOONEN, A, LENAERTS, J, LESAFFRE, E, De Vlam, Kurt, ...

Clinical assessment in the spondyloarthropathies, including psoriatic arthritis (2006)

Van Den Bosch, Filip, VANDER CRYSSEN, B, Mielants, Herman

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity (2006)

Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, WESTHOVENS, R, DUREZ, P, Van Den Bosch, Filip, ...

Prediction of dose escalation for rheumatoid arthritis patients under infliximab treatment (2006)

Van Looy, Stijn, Vander Cruyssen, Bert, Meeus, Jeroen, Wyns, Bart, WESTHOVENS, R, DUREZ, P, ...

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment (2005)

Van Looy, Stijn, Wyns, Bart, Durez, Patrick, Van Den Bosch, Filip, ...

This study is based on an expanded access program in which 511 patients suffering from active refractory rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab (3...

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment (2005)

Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, Westhovens, Rene, Durez, Patrick, Van Den Bosch, Filip, ...

Abstract This study is based on an expanded access program in which 511 patients suffering from active refractory rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab (3...

Tumor necrosis factor-α blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification? (2005)

Van Den Bosch, Filip, De Keyser, Filip, Mielants, Herman, Veys, Eric M

Abstract Blocking tumor necrosis factor-α either with monoclonal antibodies or with soluble receptor constructs has been proven to be effective with an acceptable safety profile in patients with...

The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications (2005)

De Rycke, Leen, Baeten, Dominique, Kruithof, Elli, Van Den Bosch, Filip, Veys, Eric, De Keyser, Filip

IgM anti-dsDNA autoantibodies are the main antinuclear reactivity induced by infliximab but not etanercept treatment in vivo: Biological and clinical implications (2005)

De Rycke, Leen, Baeten, Dominique, Kruithof, Elli, Van Den Bosch, Filip, Veys, Eric, De Keyser, Filip

Das28 correlates best with the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients (2005)

Vander Cruyssen, Bert, Van Looy, Stijn, WESTHOVENS, R, DUREZ, P, Van Den Bosch, Filip, VEYS, EM, ...

Impact of natural changes in disease activity on synovial histopathology in rheumatoid arthritis (2005)

Baeten, Dominique, HOUBIERS, J, Kruithof, Elli, Vandooren, Bernard, Van Den Bosch, Filip, BOOTS, A, ...

Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity - Biologic and clinical implications in autoimmune arthritis (2005)

De Rycke, Leen, Baeten, Dominique, Kruithof, Elli, Van Den Bosch, Filip, Veys, Eric, De Keyser, Filip

Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis (2005)

De Rycke, Leen, Verhelst, Xavier, Kruithof, Elli, Van Den Bosch, Filip, Hoffman, Ilse, Veys, Eric, ...

Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy (2005)

Kruithof, Elli, Baeten, Dominique, Van Den Bosch, Filip, Mielants, Herman, Veys, Eric, De Keyser, Filip

Short and long term synovial immunumodulation by etanercept in spondyloarthropathy (2005)

Kruithof, Elli, De Rycke, Leen, Van Den Bosch, Filip, Mielants, Herman, Veys, Eric, De Keyser, Filip, ...

5-year safety and efficacy follow-up in 107 spondyloarthropathy patients with continued long-term infliximab treatment (2005)

Van Den Bosch, Filip, DEVINCK, MIEKE, Kruithof, Elli, VERBRUGGEN, G, De Keyser, Filip, Mielants, Herman, ...

Tumor necrosis factor-alpha blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification? (2005)

Van Den Bosch, Filip, De Keyser, Filip, Mielants, Herman, Veys, Eric

Effective immunomodulation of peripheral joint pathology in spondyloarthropathy by etanercept (2005)

Kruithof, Elli, De Rycke, Leen, ROTH, J, Mielants, Herman, Van Den Bosch, Filip, De Keyser, Filip, ...

Preliminary evidence for a retardation of structural damage in patients with ankylosing spondylitis continuously treated with infliximab for 4 years (2005)

Van Den Bosch, Filip, DEVINCK, MIEKE, Kruithof, Elli, Hoffman, Ilse, VERBRUGGEN, G, De Keyser, Filip, ...

Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies (2005)

Kruithof, Elli, De Rycke, Leen, ROTH, J, Mielants, Herman, Van Den Bosch, Filip, De Keyser, Filip, ...

A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis (2004)

KIRWAN, JR, HALLGREN, R, Mielants, Herman, WOLLHEIM, F, BJORCK, E, PERSSON, T, ...

Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy (2004)

Vandooren, Bernard, Kruithof, Elli, YU, DTY, RIHL, M, GU, JR, De Rycke, Leen, ...

The lunar achilles as a screening tool for osteoporosis: Comparison with spine DXA (2004)

PORIAU, S, GEUSENS, P, Van Den Bosch, Filip, De Keyser, Filip

The effect of infliximab on skin lesions in a patient with scleroderma (CREST) (2004)

De Rycke, Leen, Baeten, Dominique, Van Den Bosch, Filip, Mielants, Herman, De Keyser, Filip, Veys, Eric

Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in Ankylosing spondylitis (2004)

De Keyser, Filip, Baeten, Dominique, Van Den Bosch, Filip, KRUITHOF, ELLI, VERBRUGGEN, G, Mielants, Herman, ...

Antinuclear antibodies following Infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy (2003)

De Rycke, Leen, Kruithof, Elli, VAN DAMME, NANCY, Hoffman, Ilse, Van Den Bosch, Filip, ...

Systematic safety follow-up in a cohort of 107 patients with spondylarthropathy treated with Infliximab: a new perspective of the role of host defence in the pathogenesis of the disease? (2003)

Baeten, Dominique, Kruithof, Elli, Van Den Bosch, Filip, HERSSENS, MARIANNE, Mielants, Herman, ...

Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety and biological immunomodulation (2003)

De Keyser, Filip, Baeten, Dominique, Van Den Bosch, Filip, Kruithof, Elli, Mielants, Herman, Veys, Eric

Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety, and biological immunomodulation (2003)

De Keyser, Filip, Baeten, Dominique, Van Den Bosch, Filip, Kruithof, Elli, Mielants, Herman, Veys, Eric

Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? (2003)

Baeten, Dominique, Kruithof, Elli, Van Den Bosch, Filip, HERSSENS, A, Mielants, Herman, ...

Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy (2003)

De Rycke, Leen, Kruithof, Elli, VAN DAMME, NANCY, Hoffman, Ilse, Van Den Bosch, Filip, ...

Changes in rheumatoid factor reflect the inflammatory response (CRP and ESR) to infliximab treatment (2003)

De Rycke, Leen, Kruithof, Elli, VAN DAMME, NANCY, Hoffman, Ilse, Van Den Bosch, Filip, Veys, Eric, ...

Costimulatory blockade in patients with rheumatoid arthritis a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. (2002)

MORELAND, LW, ALTEN, R, Van Den Bosch, Filip, APPELBOOM, T, LEON, M, EMERY, P, ...

Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha. (2001)

Van Den Bosch, Filip, Baeten, Dominique, Kruithof, Elli, De Keyser, Filip, Mielants, Herman, Veys, Eric

Effects of anti-tumor necrosis factor alpha on synovium in patients with spondylarthropathy: Comment on the article by Baeten et al - Reply. (2001)

Baeten, Dominique, Kruithof, Elli, Van Den Bosch, Filip, Mielants, Herman, Veys, Eric, De Keyser, Filip

A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. (2000)

EMERY, P, BREEDVELD, FC, LEMMEL, EM, KALTWASSER, JP, DAWES, PT, GOMOR, B, ...

Tumor necrosis factor-α blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification?

Van Den Bosch, Filip, De Keyser, Filip, Mielants, Herman, Veys, Eric M

Blocking tumor necrosis factor-α either with monoclonal antibodies or with soluble receptor constructs has been proven to be effective with an acceptable safety profile in patients with rheumatoid...

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment

Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, Westhovens, Rene, Durez, Patrick, Van Den Bosch, Filip, ...

This study is based on an expanded access program in which 511 patients suffering from active refractory rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab (3...

Tumor necrosis factor-α blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification?

Van Den Bosch, Filip, De Keyser, Filip, Mielants, Herman, Veys, Eric M

Blocking tumor necrosis factor-α either with monoclonal antibodies or with soluble receptor constructs has been proven to be effective with an acceptable safety profile in patients with rheumatoid...

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment

Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, Westhovens, Rene, Durez, Patrick, Van Den Bosch, Filip, ...

This study is based on an expanded access program in which 511 patients suffering from active refractory rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab (3...

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity

Cruyssen, Bert Vander, Van Looy, Stijn, Wyns, Bart, Westhovens, Rene, Durez, Patrick, Van Den Bosch, Filip, ...

Although there is strong evidence supporting the short-term efficacy and safety of anti-tumour necrosis factor-α agents, few studies have examined the long-term effects. We evaluated 511 patients...